What is adagrasib studying for solid tumors?

Adagrasib is being studied to evaluate its long-term treatment effects in patients with advanced solid tumors, including non-small cell lung and colorectal cancers. The trial aims to monitor safety and ongoing clinical benefit in participants from earlier adagrasib studies. Mirati Therapeutics Inc. sponsors the research to better understand treatment outcomes over time.

Who may be eligible for this solid tumor clinical trial?

Adults aged 18 and older who have participated in previous adagrasib parent studies and are eligible for continued treatment may qualify. Both males and females can participate, but females assigned at birth must meet certain reproductive criteria. Participants should not have stopped treatment due to progression or toxicity. Please review eligibility criteria for more details.

Is there any cost to participate in this solid tumor clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. However, personal travel expenses to and from study visits may vary and are not guaranteed to be covered. Participants should plan accordingly for any associated travel costs.

Actively Recruiting

Phase 2

Age: 18Years +

All Genders

ID07415031

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib BMS-986503

Led by Mirati Therapeutics Inc. · Updated on 2026-05-15

170

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating long-term treatment with adagrasib and other cancer therapies in patients with advanced solid tumors, including non-small cell lung cancer and colorectal cancer. This open-label continuation trial enrolls participants from ongoing parent studies that previously assessed adagrasib alone or in combination with other treatments. The purpose is to monitor ongoing treatment effects and safety in these participants. The study involves multiple experimental groups receiving specified doses of adagrasib and other drugs such as pembrolizumab, cetuximab, pemetrexed, docetaxel, irinotecan, leucovorin, oxaliplatin, and fluorouracil on specified days. Participants continue treatment as defined by their parent study or investigator assessment of clinical benefit. This trial allows continued access to study treatments following previous participation. Participants will be monitored for adverse events, serious adverse events, and treatment discontinuations related to side effects for up to 90 days after the last dose or stopping the study. Safety evaluations and clinical benefits are assessed according to parent study protocols and investigator judgment. The trial is expected to last until February 2028, with ongoing observation of participants responses and tolerability.

CONDITIONS

Brief Title

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Participant is eligible to receive continued study treatment as per the parent study or investigator-assessed clinical benefit.
Individuals assigned female sex at birth must have documented proof of not being of childbearing potential.
Sexually active individuals of childbearing potential must agree to follow contraception instructions.
Participant is aged 18 years or older.

You will not qualify if you...

Participant is not eligible for study treatment per the parent study eligibility criteria.
Participants who completed treatment, progressed, or discontinued study treatment due to toxicity in the parent study are not eligible.
Participants not receiving clinical benefit from the parent study drug as assessed by the investigator.
Other protocol-defined exclusion criteria may apply.

Research Team

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here